Clinical and radiological factors affecting progression in sarcoidosis
Keywords:
Sarcoidosis, Progression, Lymph NodeAbstract
Background and aim: To determine the clinical and radiological indicators of disease progression in a newly diagnosed sarcoidosis patient.
Methods: The data of patients who were diagnosed with sarcoidosis in our department between January 2014 and June 2022 were analyzed. The patients were divided into two groups: progression and non-progression.
Groups were compared according to symptoms at the time of diagnosis, comorbidities, foci of extrapulmonary involvement, shape, size, density, and localization of mediastinal lymph nodes, parenchymal findings, disease stage and whether or not treatment was received at the beginning.
Results: The study included 292 sarcoidosis patients. The number of patients who progressed was 46 (15.8%). It was observed that stage II patients progressed more than stage I patients (p<0,001).
The mean time to progression was 38.05±30.45 months in stage I and 28±58 months in stage II patients. Progression rate was higher in patients with right upper paratracheal, subaortic-paraaortic, subcarinal LAP (p= 0.010, p= 0.012, p= 0.020, respectively). The higher number of stations with LAP was associated with the presence of progression (p=0.017). The presence of parenchymal nodules (29/64.4%) and the number of lobes with nodules was also associated with progression (p= 0.027, 0.022, respectively). Progression rate was 76.1% in patients with treatment indication at the time of diagnosis (p<0.001).
Conclusions: Disease stage is a prognostically important factor in the course of sarcoidosis, which is supported by our study results. Accordingly, it is important to follow patients with high-stage sarcoidosis more closely and to identify patients with treatment indications in time.
References
1. Seve P, Pacheco Y, Durupt F, et al. Sarcoidosis: A Clinical Overview from Symptoms to Diagnosis. Cells. 2021;10:766. doi: 10.3390/cells10040766
2. Sawahata M, Yamaguchi T. Imaging Findings of Fibrosis in Pulmonary Sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis. 2022;39(2):e2022018. doi: 10.36141/svdld.v39i2.12995
3. Judson MA, Boan AD, Lackland DT. The clinical course of sarcoidosis: presentation, diagnosis, and treatment in a large white and black cohort in the United States. Sarcoidosis Vasc Diffuse Lung Dis. 2012; 29; 119-127
4. Malkova A, Zinchenko Y, Starshinova A, et al. Sarcoidosis: Progression to the chronic stage and pathogenic based treatment (narrative review). Front Med (Lausanne). 2022(6);9:963435. doi: 10.3389/fmed.2022.963435
5. Belperio JA, Fishbein MC, Abtin F, Channick J, Balasubramanian SA, Lynch III JP. Pulmonary sarcoidosis: A. comprehensive review: Past to present. J Autoimmun. 2024; 149:103107. doi: 10.1016/j.jaut.2023.103107
6. Crouser ED, Maier LA, Wilson KC, et al. Diagnosis and Detection of Sarcoidosis. An Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med. 2020;201(8):e26-e51. doi: 10.1164/rccm.202002-0251ST
7. Statement on Sarcoidosis. Statement of The American Throcic Society (ATS), The European Respiratory Society (ERS) and The World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) Was Adopted by The ATS Board of Directors and by The ERS Executive Committee, February 1999. Am J Respir Crit Care Med. 1999;160: 736-755. doi: 10.1164/ajrccm.160.2.ats4-99
8. Thillai M, Atkins CP, Crawshaw A, et al. BTS Clinical Statement on pulmonary sarcoidosis. 2021 Jan;76(1):4-20. doi: 10.1136/thoraxjnl-2019-214348
9. Peros-Golubicic T, Ivicevic A, Bekić A, Alilovic M, Tekavec-Trkanjec J, Smojver-Jezek S. Lung lavage neutrophils, neutrophil elastase and albumin in the prognosis of pulmonary sarcoidosis. Coll Antropol. 2001;25:349-55
10. Feng H, Yan L, Zhao Y, Li Z, Kang J. Neutrophils in bronchoalveolar lavage fluid indicating the severity and relapse of pulmonary sarcoidosis. Front Med. 2022;8:3125. doi: 10.3389/fmed.2021.787681
11. Drent M, Jacobs JA, de Vries J, Lamers RJS, Liem IH, Wouters EFM. Does the cellular bronchoalveolar lavage fluid profile reflect the severity of sarcoidosis? Eur Respir J. 1999;13:1338-44. doi: 10.1183/09031936.99.13613459
12. Ziegenhagen MW, Benner UK, Zissel G, Zabel P, Schlaak M, Müller-Quernheim J. Sarcoidosis: TNF Release from Alveolar Macrophages and Serum Level of sIL-2R Are Prognostic Markers. Am J Respir Crit Care Med. 1997;156:1586-1592. doi: 10.1164/ajrccm.156.5.97-02050
13. Bergantini L, Bianchi F, Cameli P, et al. Prognostic biomarkers of sarcoidosis: A comparative study of serum chitotriosidase, ACE, lysozyme, and KL-6. Dis Markers. 2019:8565423. doi: 10.1155/2019/8565423
14. Casal A , Suarez-Antelo J, Soto-Feijóo R , et al. Sarcoidosis. Disease progression based on radiological and functional courses: predictive factors. Heart Lung. 2022;56:62-69. doi: 10.1016/j.hrtlng.2022.06.020
15. Bilgin B, Bilgin MK, Erol S, Celik G, Kumbasar OO. Prognosis of sarcoidosis and factors affecting prognosis. Sarcoidosis Vasc Diffuse Lung Dis. 2023; 40 (4): e2023054. doi: 10.36141/svdld.v40i4.13244
16. Silva AL, Melo N, Mota PC, et al. Pulmonary Sarcoidosis: Prognostic Factors at Diagnosis in Patients from North of Portugal. Reumatol Clin (Engl Ed). 2020;16(6):468-472. doi: 10.1016/j.reuma.2018.10.004
17. Criado E, Sánchez M, Ramírez J, et al. Pulmonary sarcoidosis: typical and atypical manifestations at high-resolution CT with pathologic correlation. Radiographics. 2010;30:1567-86. doi: 10.1148/rg.306105512
18. Benn BS, Lippitt WL, Cortopassi I, et al. Understanding the Added Value of High-Resolution CT Beyond Chest X-Ray in Determining Extent of Physiologic Impairment. Chest. 2024;166(5):1093-1107. doi: 10.1016/j.chest.2024.04.031
19. Koc AS, Oncel G, Ince O, Sever F, Kobak S. The role of chest X-ray in the early diagnosis and staging of sarcoidosis: Is it really should be done? Reumatol Clin (Engl Ed). 2023 Dec;19(10):560-564. doi: 10.1016/j.reumae.2023.10.003
20. Desai SR, Sivarasan N, Johannson KA, et al. High-resolution CT phenotypes in pulmonary sarcoidosis: a multinational Delphi consensus study. Lancet Respir Med. 2024 May;12(5):409-418. doi: 10.1016/S2213 2600(23)00267 9
21. Castro MDC, Pereira CAC, Soares MR. Prognostic features of sarcoidosis course in a Brazilian cohort. J Bras Pneumol. 2022;48(1):e20210366. doi: 10.36416/1806-3756/e20210366
Downloads
Published
Issue
Section
License
Copyright (c) 2025 Olcay Aycicek, Ensar Cihat Emiroglu, Kadir Coban, Muge Erbay, Tevfik Ozlu, Funda Oztuna, Yılmaz Bulbul
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Transfer of Copyright and Permission to Reproduce Parts of Published Papers.
Authors retain the copyright for their published work. No formal permission will be required to reproduce parts (tables or illustrations) of published papers, provided the source is quoted appropriately and reproduction has no commercial intent. Reproductions with commercial intent will require written permission and payment of royalties.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
